Arachidonic Acid
CAS 506-32-1
Arachidonic Acid (CAS 506-32-1) is a pharmaceutical compound with 5 bioactivity targets and 10 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 22356.778125 nM | 43 | - |
| - | IC50 | 24953.679428571428 nM | 35 | - |
| - | EC50 | 69422.5 nM | 4 | - |
| - | Kd | 25090 nM | 2 | - |
| - | Ki | 575 nM | 2 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| ClC-2 CLCN2 |
Activator | - | - |
| K 2P 10.1 KCNK10 |
Activator | - | 10880510 |
| K 2P 13.1 | Activator | - | 25148687 |
| K 2P 18.1 KCNK18 |
Inhibitor | - | 12754259 |
| K 2P 2.1 KCNK2 |
Activation | 5.0 pEC50 | 9687497 |
| K 2P 3.1 KCNK3 |
Channel blocker | 1.0 pIC50 | 11226154 |
| K 2P 4.1 KCNK4 |
Activator | - | 9628867 |
| K 2P 4.1 Kcnk4 |
Positive | - | 7623282 |
| K ir 2.3 KCNJ4 |
Agonist | 6.35 pEC50 | 11306688 |
| K ir 3.4 Kcnj5 |
Agonist | - | 2492640 |
| K v 4.2 Kcnd2 |
Channel blocker | 5.699999809265137 pIC50 | 10503950|8786428 |
| Maxi Cl - | Channel blocker | - | - |
| TRPC6 TRPC6 |
Activator | - | - |
| TRPM2 TRPM2 |
Potentiation | - | 11804595 |
| TRPV4 Trpv4 |
Activation | 5.0 pEC50 | 12879072 |
| VRAC | Channel blocker | - | - |
| protein kinase C zeta PRKCZ |
Activation | - | 7744003 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Arachidonic Acid used for in pharmaceutical contexts?
Arachidonic Acid (CAS 506-32-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Arachidonic Acid?
Arachidonic Acid has 10 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug ineffective, Exposure during pregnancy, Fever neonatal, Foetal exposure during pregnancy, Sepsis neonatal. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Arachidonic Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for ARACHIDONIC ACID with EU status "permitted".
What clinical phase is Arachidonic Acid in?
No phase 1-4 clinical development badge is rendered for Arachidonic Acid because the matched compound identifier rows do not contain a max-phase value.